川宁生物
(301301)
| 流通市值：51.39亿 | | | 总市值：185.28亿 |
| 流通股本：6.19亿 | | | 总股本：22.32亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 2,097,724,481.88 | 1,094,498,381.4 | 4,616,269,644.24 | 3,435,984,280.4 |
| 营业总成本 | 1,749,676,349.85 | 953,571,535.58 | 3,647,312,221.12 | 2,650,557,983.64 |
| 其他经营收益 | | | | |
| 营业利润 | 343,114,264.8 | 142,448,769.31 | 956,987,877.05 | 767,936,150.29 |
| 利润总额 | 337,302,909.13 | 138,705,161.75 | 938,685,807.74 | 751,774,796.43 |
| 净利润 | 274,081,202.28 | 110,017,785.81 | 768,346,157.39 | 610,903,946.61 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | 289,923.58 | - |
| 综合收益总额 | 274,081,202.28 | 110,017,785.81 | 768,636,080.97 | 610,903,946.61 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 4,241,934,859.52 | 4,190,899,627.78 | 4,209,095,420.61 | 4,021,681,016.89 |
| 非流动资产: | | | | |
| 非流动资产合计 | 6,089,462,260.75 | 6,212,043,937.47 | 6,220,384,857.36 | 6,309,096,664.5 |
| 资产总计 | 10,331,397,120.27 | 10,402,943,565.25 | 10,429,480,277.97 | 10,330,777,681.39 |
| 流动负债: | | | | |
| 流动负债合计 | 1,769,457,630.17 | 1,631,112,412.06 | 1,744,373,301.79 | 1,801,064,638.99 |
| 非流动负债: | | | | |
| 非流动负债合计 | 556,129,226.02 | 553,384,132.89 | 577,274,160.93 | 578,203,091.88 |
| 负债合计 | 2,325,586,856.19 | 2,184,496,544.95 | 2,321,647,462.72 | 2,379,267,730.87 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 7,983,869,525.79 | 8,193,790,290.38 | 8,082,466,755.3 | 7,925,970,346.14 |
| 股东权益合计 | 8,005,810,264.08 | 8,218,447,020.3 | 8,107,832,815.25 | 7,951,509,950.52 |
| 负债和股东权益合计 | 10,331,397,120.27 | 10,402,943,565.25 | 10,429,480,277.97 | 10,330,777,681.39 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 1,906,245,325.31 | 597,894,252.34 | 3,486,928,076.92 | 2,827,254,076.42 |
| 经营活动现金流出小计 | 1,130,892,490.55 | 415,213,316.39 | 2,937,868,598.59 | 2,256,312,811.11 |
| 经营活动产生的现金流量净额 | 775,352,834.76 | 182,680,935.95 | 549,059,478.33 | 570,941,265.31 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 770,900,474.09 | 550,606,794.64 | 2,791,038,762.64 | 1,922,030,527.48 |
| 投资活动现金流出小计 | 1,022,894,314.43 | 620,055,837.71 | 3,022,970,881.58 | 2,224,002,533.45 |
| 投资活动产生的现金流量净额 | -251,993,840.34 | -69,449,043.07 | -231,932,118.94 | -301,972,005.97 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 408,768,530.48 | 200,000,000 | 768,125,956.81 | 520,125,383.01 |
| 筹资活动现金流出小计 | 786,232,944 | 378,817,242.65 | 1,442,041,802.33 | 1,129,180,136.76 |
| 筹资活动产生的现金流量净额 | -377,464,413.52 | -178,817,242.65 | -673,915,845.52 | -609,054,753.75 |
| 汇率变动对现金及现金等价物的影响 | -4,577,612.08 | -5,105,726.25 | 2,670,112.45 | 2,265,910.67 |
| 现金及现金等价物净增加额 | 141,316,968.82 | -70,691,076.02 | -354,118,373.68 | -337,819,583.74 |
| 期末现金及现金等价物余额 | 875,530,269.75 | 663,522,224.91 | 734,213,300.93 | 747,584,795.32 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 141,316,968.82 | - | -354,118,373.68 | - |
最新报告期：2026-08-26| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 中泰证券 | 祝嘉琦 | 0.34 | 0.38 | 0.40 | 2026-08-26 |